Melatonin and the Metabolic Syndrome (MetSyn)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01038921
Recruitment Status : Completed
First Posted : December 24, 2009
Results First Posted : May 1, 2014
Last Update Posted : February 27, 2015
Information provided by (Responsible Party):
Michael Kutner, Emory University

December 22, 2009
December 24, 2009
August 13, 2013
May 1, 2014
February 27, 2015
July 2009
June 2012   (Final data collection date for primary outcome measure)
Metabolic Syndrome Components [ Time Frame: 3 years ]
Same as current
Complete list of historical versions of study NCT01038921 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Melatonin and the Metabolic Syndrome
Melatonin Supplementation and the Metabolic Syndrome: A Phase II Crossover Design Clinical Trial
This trial seeks to compare the effects of melatonin supplementation versus placebo in subjects with the metabolic syndrome.
The primary purpose of this Phase II crossover design trial is to examine the safety and efficacy of 8mg of melatonin taken one hour before bedtime compared to a placebo treatment to improve at least one of the five components associated with the metabolic syndrome.
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Metabolic Syndrome
  • Drug: Melatonin
    8 mg dose of Melatonin
  • Drug: Placebo
  • Experimental: Melatonin
    Melatonin 8mg one hour before bedtime for 10 weeks
    Intervention: Drug: Melatonin
  • Placebo Comparator: Placebo
    Placebo administered 1 hour before bedtime for 10 weeks
    Intervention: Drug: Placebo
Goyal A, Terry PD, Superak HM, Nell-Dybdahl CL, Chowdhury R, Phillips LS, Kutner MH. Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial. Diabetol Metab Syndr. 2014 Nov 18;6:124. doi: 10.1186/1758-5996-6-124. eCollection 2014.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2013
June 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age 30-79 years.
  2. Diagnosed with metabolic syndrome according to AdenosineTriphosphate-III criteria.
  3. Availability for six months after enrolling in the study.

Exclusion Criteria:

  1. Inability to understand informed consent and to cooperate with study procedures.
  2. Supplemental intake of melatonin.
  3. Current smoking.
  4. Current use of calcium channel blockers.
  5. Current, planned, or recent (12 months) participation in another clinical trial.
  6. Women who are pregnant, breast-feeding, attempting conception, or planning to attempt conception over the next 6 months.
  7. Presence of any of the following diagnosed health conditions:

    • Active malignancy other than nonmelanoma skin cancer (current therapy for this malignancy,diagnosis within five years of enrollment, recurrence within five years of enrollment, or metastasis)
    • Uncontrolled hypothyroidism or hyperthyroidism
    • Recent (< 1 year ago) history of heart attack, bypass surgery, angioplasty, or stroke
    • Heart failure (New York Heart Association functional class 3 or 4)
    • On renal dialysis
    • Immunosuppressive therapy (systemic corticosteroids, azathioprine, methotrexate, cyclophosphamide,
    • etc.) or an immunodeficiency syndrome
    • Narcotic or alcohol dependence
    • Obstructive sleep apnea (OSA) , defined either by previous diagnosis (with or without use of nasal CPAP), or by a score of 0.80 or higher on the MAP (Multivariate Apnea Prediction), a validated screening algorithm with high positive and negative predictive value for identifying OSA.
  8. Shift-workers.
Sexes Eligible for Study: All
30 Years to 79 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
R21AT004220-01A2 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Michael Kutner, Emory University
Emory University
Not Provided
Principal Investigator: Michael H Kutner, PhD Emory University
Study Director: Abinav Goyal, M.D. Emory University
Emory University
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP